Evidence map›Paper›PMID 33575322›Full record

Trial reportBioMed research international2021

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.

Weihua Cao, Minghui Li, Lu Zhang, Yao Lu, Shuling Wu, Ge Shen, Min Chang, Ruyu Liu, Yuanjiao Gao, Hongxiao Hao and 4 more

Open access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 2 countries.

Weihua CaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.ORCID https://orcid.org/0000-0003-3233-5473
Lu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.ORCID https://orcid.org/0000-0002-3644-5306
Yao LuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.ORCID https://orcid.org/0000-0002-3422-0082
Shuling WuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Ge ShenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Min ChangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Ruyu LiuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Yuanjiao GaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Hongxiao HaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Leiping HuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.
Wei YiDepartment of Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang District, Beijing 100015, China.ORCID https://orcid.org/0000-0003-4241-8205
Calvin Q PanCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.ORCID https://orcid.org/0000-0002-3723-6688
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang, Beijing 100015, China.ORCID https://orcid.org/0000-0002-6563-5803
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo explore the role of natural killer (NK) cells in the process of hepatitis B virus (HBV) clearance and whether their phenotype is related to antiviral treatment outcome in chronic hepatitis B (CHB) patients.

methodWe performed a single-center prospective cohort study to analyze changes of NK cells at weeks 12 and 24 from baseline in CHB patients who received PEGylated-interferon- (PEG-IFN-)

resultsIn PEG-IFN-

conclusionsIn CHB patients, PEG-IFN-

Indexed as

Hepatitis B, ChronicAdultAntiviral AgentsFemaleGuanineHumansInterferon-alphaKiller Cells, NaturalMaleMiddle AgedPolyethylene GlycolsProspective StudiesRecombinant ProteinsYoung AdultAntiviral AgentsentecavirGuanineInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteins

Identifiers

PMID33575322
PMCPMC7857883
OpenAlexW3126329520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.